Review
Pharmacology & Pharmacy
Yifeng Cao, Chuyang Chen, Yi Tao, Weifeng Lin, Ping Wang
Summary: Triple-negative breast cancer (TNBC) is characterized by extensive tumor heterogeneity at both the pathologic and molecular levels, leading to increased mortality of patients due to accelerated aggressiveness and terrible metastasis. Hindered by the negative expression of certain receptors, targeted therapy has been challenging, but the higher immune response in TNBC compared to other breast cancer types makes it suitable for immunotherapy.
Review
Immunology
Melina Farshbafnadi, Amin Pastaki Khoshbin, Nima Rezaei
Summary: Breast cancer, especially the triple-negative subtype, poses challenges for treatment due to lack of actionable targets. Immune checkpoint inhibitors have shown promise in TNBC treatment, and their combination with chemotherapy may be beneficial for patients with metastatic or early-stage disease. Clinical trials have provided evidence supporting the use of immune checkpoint blockade in TNBC management.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Oncology
Flavia Jacobs, Elisa Agostinetto, Chiara Miggiano, Rita De Sanctis, Alberto Zambelli, Armando Santoro
Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. Chemotherapy has been the mainstay, but recent studies have shown immune checkpoint inhibitors to be effective as first-line treatment for advanced TNBC expressing PD-L1. However, there are still many open questions regarding the use of immunotherapy in TNBC.
Review
Biochemistry & Molecular Biology
Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Jiang Yi, Jiawen Bu, Zhenyong Zhang, Peng Qiu, Xi Gu
Summary: Immunotherapy has emerged as a promising strategy for treating triple-negative breast cancer (TNBC), which stimulates the immune system to kill tumor cells and offers new hope for patients. Breakthroughs in immune checkpoint inhibitors (ICIs) have led to individualized immunotherapy schedules and the combination with other treatment methods to overcome drug resistance.
Review
Oncology
Dorota Kwapisz
Summary: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis and limited treatment options, but it shows higher immunogenicity, tumor-infiltrating lymphocytes (TILs) enrichment, and programmed cell death ligand 1 (PD-L1) expression which make it more suitable for immune checkpoint blockade therapy. Patients with PD-L1-positive TNBC subgroup may benefit the most from immune checkpoint inhibitor (ICI) treatment, and ICI given as first-line treatment in advanced TNBC shows better results than in later lines of treatment. Exciting results have been seen with pembrolizumab in early-stage TNBC, indicating potential approval in (neo)adjuvant settings in the near future.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Multidisciplinary Sciences
Dora Hammerl, John W. M. Martens, Mieke Timmermans, Marcel Smid, Anita M. Trapman-Jansen, Renee Foekens, Olga I. Isaeva, Leonie Voorwerk, Hayri E. Balcioglu, Rebecca Wijers, Iris Nederlof, Roberto Salgado, Hugo Horlings, Marleen Kok, Reno Debets
Summary: Only a subset of triple-negative breast cancer patients respond to immunotherapy, with spatial immune contextures analyzed in relation to genomic alterations, mechanisms of T cell evasion, and response to anti-PD1 treatment. The study identified various immune phenotypes associated with resistance or response to anti-PD1, providing insights into the complex interactions within the tumor microenvironment.
NATURE COMMUNICATIONS
(2021)
Review
Cell Biology
Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti
Summary: A meta-analysis showed that neoadjuvant chemoimmunotherapy in TNBC patients is associated with higher pathological complete response rate, regardless of PD-L1 status.
Review
Immunology
Flavia Sardela de Miranda, Maribel Castro, Nicole Remmert, Sharda P. Singh, Rakhshanda Layeequr Rahman, Michael W. Melkus
Summary: Breast cancer is the second most common cancer among women in the United States, and surgery is the standard treatment. Cryoablation, a potential alternative to surgical resection, can destroy the tumor using extreme cold temperatures while preserving potential tumor antigens. However, combination with immune activation therapies, such as immune checkpoint inhibitors, may be necessary for maximizing the immunologic benefit.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Hyungjoo Kim, Je-Min Choi, Kyung-min Lee
Summary: Immune checkpoint blockades have greatly improved cancer treatment, but a significant number of TNBC patients do not respond to these therapies, and mechanisms of resistance are poorly understood. This review focuses on biomarkers and recent advances in understanding molecular mechanisms of resistance to ICBs in TNBC.
Article
Oncology
Hugo Arasanz, Ana Isabel Bocanegra, Idoia Morilla, Joaquin Fernandez-Irigoyen, Maite Martinez-Aguillo, Lucia Teijeira, Maider Garnica, Ester Blanco, Luisa Chocarro, Karina Ausin, Miren Zuazo, Gonzalo Fernandez-Hinojal, Miriam Echaide, Leticia Fernandez-Rubio, Sergio Pineiro-Hermida, Pablo Ramos, Laura Mezquita, David Escors, Ruth Vera, Grazyna Kochan
Summary: This study investigated the role of baseline circulating low-density neutrophils (LDN) in NSCLC patients, identifying LDN as a predictive biomarker for immunotherapy resistance. Combining immunotherapy with chemotherapy can reduce LDN levels, overcome resistance, and suggest potential drug combinations for improved outcomes.
Review
Oncology
Juan Zhang, Qi Tian, Mi Zhang, Hui Wang, Lei Wu, Jin Yang
Summary: Breast cancer is a common female cancer worldwide, with triple-negative breast cancer being one of the most dangerous subtypes with high mortality and relapse rates. Immunotherapy has become a promising and effective treatment, but not all patients are sensitive to it, highlighting the importance of selecting suitable candidates for immunotherapy. Recent discoveries in immune-related factors of TNBC offer insights into predicting prognosis and response to immunotherapy.
Review
Medicine, General & Internal
Jieun Lee
Summary: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer, accounting for 15-20% of cases, with a high rate of recurrence despite chemotherapy. Conventional cytotoxic chemotherapy with anthracyclines and taxanes remains the main treatment option. Achievement of pathologic complete response (pCR) is associated with improved survival outcomes, leading to the shift towards neoadjuvant treatment and investigation of intensified chemotherapy and post-neoadjuvant therapy. This article reviews the current treatment landscape for early TNBC, from standard cytotoxic chemotherapy to immune checkpoint inhibitors, capecitabine, and olaparib.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Alyssa Vito, Stephanie Rathmann, Natalie Mercanti, Nader El-Sayes, Karen Mossman, John Valliant
Summary: The study investigated the combination of radionuclide therapy and immunotherapy for breast cancer, finding that neither monotherapy improved therapeutic outcomes, but the combination significantly extended overall survival and reduced necrotic tissue within the tumor, as well as suppressed inflammatory cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Genetics & Heredity
Shaojun Hu, Xiusheng Qu, Yu Jiao, Jiahui Hu, Bo Wang
Summary: The study classified TNBC into immune subtypes and discovered significant differences in prognosis, gene mutation, immune infiltration, drug sensitivity, and heterogeneity among subtypes. The findings validate the independent role of immune subtypes in tumor progression and immunotherapy for TNBC, offering a new perspective for personalized immunotherapy and prognosis evaluation of TNBC patients in the future.
FRONTIERS IN GENETICS
(2021)
Review
Oncology
Arielle L. Heeke, Antoinette R. Tan
Summary: Immunotherapy has become a key component in the treatment of cancer, with promising activity observed in metastatic triple-negative breast cancer (TNBC) through PD-1/PD-L1 checkpoint inhibitor therapy. Accelerated approvals by the FDA for atezolizumab and pembrolizumab in 2019 and 2020, respectively, have provided hope for the treatment of PD-L1-positive TNBC.
CANCER AND METASTASIS REVIEWS
(2021)
Review
Oncology
Jun He, Li Xiong, Qinglong Li, Liangwu Lin, Xiongying Miao, Shichao Yan, Zhangyong Hong, Leping Yang, Yu Wen, Xiyun Deng
Article
Nanoscience & Nanotechnology
Liujiang Song, Xiaojun Tao, Li Lin, Chao Chen, Hui Yao, Guangchun He, Guangyang Zou, Zhong Cao, Shichao Yan, Lu Lu, Huimei Yi, Di Wu, Siyuan Tan, Warain Ouyang, Zhifei Dai, Xiyun Deng
ACS APPLIED MATERIALS & INTERFACES
(2018)
Article
Oncology
Liang Zeng, Xiyun Deng, Jingmin Zhong, Li Yuan, Xiaojun Tao, Sai Zhang, Yong Zeng, Guangchun He, Pingping Tan, Yongguang Tao
Article
Nanoscience & Nanotechnology
Di Wu, Yao Chen, Shun Wen, Yi Wen, Rong Wang, Qiuting Zhang, Ge Qin, Huimei Yi, Mi Wu, Lu Lu, Xiaojun Tao, Xiyun Deng
NANOSCALE RESEARCH LETTERS
(2019)
Article
Oncology
Chanjuan Zheng, Shichao Yan, Lu Lu, Hui Yao, Guangchun He, Sisi Chen, Ying Li, Xiaojun Peng, Zhongyi Cheng, Mi Wu, Qiuting Zhang, Guifei Li, Shujun Fu, Xiyun Deng
Summary: Lovastatin inhibits EMT and metastasis of TNBC CSCs by dysregulating lysine succinylation of cytoskeleton-associated proteins, down-regulating Vimentin and Twist protein levels, and disrupting the cytoskeleton, leading to reduced migration and liver metastasis. Bioinformatics analysis suggests that cytoskeleton-associated genes are characteristic of TNBC and may predict survival outcomes in breast cancer patients.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Mi Wu, Lu Lu, Sisi Chen, Ying Li, Qiuting Zhang, Shujun Fu, Xiyun Deng
Summary: The nucleolus, a site of ribosome biogenesis, has been found to play a crucial role in cancer development. Recent studies have shown that the nucleolus controls various cellular functions related to cancer development and induction of nucleolar stress has emerged as a promising therapeutic approach. Natural products have been discovered as effective inducers of nucleolar stress, paving the way for novel anti-cancer drugs.
Review
Oncology
Ying Li, Zhijun Zhan, Xuemin Yin, Shujun Fu, Xiyun Deng
Summary: TNBC, characterized by absence of ER, PR, and HER2 expression, is a highly aggressive subtype of breast cancer. Conventional chemotherapy remains the main treatment, but the lack of targeted therapies has led to exploration of PARP inhibitors and immune checkpoint inhibitors as potential options. Other agents targeting various pathways are also under investigation.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Sisi Chen, Ying Li, Muyao Wu, Lian Xue, Jianyu Zhu, Mi Wu, Qiuting Zhang, Guangchun He, Guifei Li, Shujun Fu, Chanjuan Zheng, Xiyun Deng
Summary: The study found that NOLC1 is highly expressed in TNBC and is associated with tumor stem cell characteristics and poor prognosis in breast cancer, suggesting it may be a potential therapeutic target for TNBC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Zhe-Yu Hu, Chanjuan Zheng, Jianbo Yang, Siyu Ding, Can Tian, Ning Xie, Lian Xue, Muyao Wu, Shujun Fu, Zhouzhou Rao, Matthew A. Price, James B. McCarthy, Quchang Ouyang, Jizhen Lin, Xiyun Deng
Summary: In triple-negative breast cancer (TNBC), co-expression of CSPG4 and PDL1 may have prognostic value and therapeutic implications.
FRONTIERS IN ONCOLOGY
(2022)
Editorial Material
Oncology
Xiyun Deng, Chanjuan Zheng, Faqing Tang, Thomas J. J. Rosol, Zhi-Ming Shao
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Chanjuan Zheng, Xi Xu, Muyao Wu, Lian Xue, Jianyu Zhu, Hongzhuo Xia, Siyu Ding, Shujun Fu, Xinyu Wang, Yian Wang, Guangchun He, Xia Liu, Xiyun Deng
Summary: Triple-negative breast cancer (TNBC) is highly lethal with limited treatment options. Neutrophils, the most abundant leukocytes, play a significant role in TNBC immunobiology. They promote tumor cell survival, proliferation, metastasis, and modulate the immune microenvironment. Neutrophils can be used as a prognostic marker and therapeutic target in TNBC.
BREAST CANCER RESEARCH
(2023)
Article
Oncology
Qiuting Zhang, Huimei Yi, Hui Yao, Lu Lu, Guangchun He, Mi Wu, Chanjuan Zheng, Ying Li, Sisi Chen, Lewei Li, Hongyuan Yu, Guifei Li, Xiaojun Tao, Shujun Fu, Xiyun Deng
Summary: Artemisinin derivatives such as artemisinin and dihydroartemisinin have shown anti-proliferative effects on non-small cell lung cancer (NSCLC) cells by inducing apoptosis and ferroptosis. These findings suggest the potential application of artemisinin derivatives as novel therapeutic drugs for NSCLC.
Article
Materials Science, Biomaterials
Shichao Yan, Da Tang, Zhangyong Hong, Jing Wang, Hui Yao, Lu Lu, Huimei Yi, Shujun Fu, Chanjuan Zheng, Guangchun He, Heng Zou, Xuyang Hou, Qing He, Li Xiong, Qinglong Li, Xiyun Deng
Summary: The study demonstrates that the novel photosensitizer CD133-Pyro can enhance the targeting properties for treating CRC, showing therapeutic effects on CRC CSCs by promoting ROS production, suppressing stemness properties, and inducing autophagic cell death. CD133-Pyro PDT has a significant inhibitory effect on CRC CSC-derived xenograft tumors in nude mice.
BIOMATERIALS SCIENCE
(2021)
Article
Oncology
Huimei Yi, Mi Wu, Qiuting Zhang, Lu Lu, Hui Yao, Sisi Chen, Ying Li, Chanjuan Zheng, Guangchun He, Xiyun Deng